LC-MS Potency Assay for Coding Nucleic Acid Translation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a rapid, cost-effective, and reliable potency assay to measure, determine, identify, quantify, and validate the therapeutic potential of nucleic acids, particularly RNA and DNA, which can be easily adapted to new products, especially in the context of nucleic acid-based therapeutics where antibodies for detection are often unavailable.
Innovation Solution
A LC-MS potency assay is developed to measure the translation of nucleic acids into peptides, using animal cell lines like CHO cells that mimic target cell mechanisms, with a readout indicative of product quality and stability, and quantified using LC-MS/MS analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional potency assays are used for nucleic acid therapeutics, then measurement of biological effect is achieved, but the assays are complex, costly, and difficult to adapt to new products
Solution Approach 1:
The patent extracts and measures only the critical functional output (peptide translation) rather than attempting to measure all aspects of biological activity. By focusing on the translation step as a proxy for therapeutic potential, the assay simplifies the measurement process while maintaining predictive accuracy for in vivo efficacy.
Solution Approach 2:
The patent introduces an intermediary measurement approach using LC-MS to detect peptide translation as a surrogate marker for therapeutic potential. This intermediary measure (peptide quantification) is easier to perform than direct in vivo efficacy testing and serves as a reliable predictor of biological activity.
2Measurement precision
If antibodies for detection are used in potency assays, then specific protein detection is achieved, but availability becomes problematic for new nucleic acid products
Solution Approach 1:
Instead of relying on specific antibodies that may not be available for new products, the patent uses LC-MS mass spectrometry to detect and quantify translated peptides. This analytical technique provides universal applicability across different nucleic acid therapeutics without requiring product-specific antibodies, thereby enhancing adaptability while maintaining detection specificity through mass spectral fingerprinting.
3Reliability
If comprehensive potency assays are developed for each nucleic acid product, then product quality control is ensured, but development time and cost increase significantly
Solution Approach 1:
The patent develops a universal potency assay platform based on LC-MS peptide quantification that can be applied across multiple nucleic acid therapeutic products. The assay measures translation of the encoded peptide as a consistent quality attribute, enabling multi-functional use for different products without requiring separate assay development for each, thus reducing time and cost while maintaining reliable quality assurance.
4Measurement precision
If in vivo clinical efficacy testing is used to determine potency, then therapeutic potential is accurately measured, but the process becomes lengthy and impractical for routine QC
Solution Approach 1:
The patent performs preliminary in vitro translation assays using cell-free or cellular systems before in vivo testing. By measuring peptide translation in controlled in vitro conditions, the assay provides a rapid preliminary assessment of therapeutic potential that predicts in vivo efficacy without requiring immediate animal or human studies, thereby increasing productivity while maintaining measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay provides a reliable and predictive measure of nucleic acid product quality by assessing cellular uptake and translation, reflecting biological activity and stability, suitable for batch release in QC environments.
Implementation Method 1
with a readout indicative of product quality and stability, and quantified using LC-MS/MS analysis
Data Source
AI summary
The invention provides potency assays for measuring, determining, identifying, quantifying, confirming, and/or validating the therapeutic potential of nucleic acid such as RNA encoding a pharmaceutically active peptide or polypeptide. The potency assays may be performed with nucleic acid such as RNA encoding various types of peptides or polypeptides, including pharmaceutically active peptides or polypeptides comprising one or more antigens or one or more epitopes. Nucleic acid such as RNA having therapeutic potential may be useful in downstream clinical applications, e.g., for eliciting an immune response against one or more antigens or one or more epitopes encoded by the nucleic acid in a subject which immune response may be therapeutic or partially or fully protective. Thus, the nucleic having therapeutic potential may be useful for vaccination.